Otsuka Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Otsuka Holdings yıllık ortalama 1.4% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 3.4% annual. Gelirler growing yılda ortalama 10.5% oranında artmaktadır. Otsuka Holdings'in özkaynak karlılığı 6.1% ve net marjı 6.7%'dir.

Anahtar bilgiler

1.4%

Kazanç büyüme oranı

1.4%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	3.4%
Gelir büyüme oranı	10.5%
Özkaynak getirisi	6.1%
Net Marj	6.7%
Sonraki Kazanç Güncellemesi	14 Feb 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Nov 04

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

Aug 05

Getting In Cheap On Otsuka Holdings Co., Ltd. (TSE:4578) Might Be Difficult

Jul 14

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 02

Is There An Opportunity With Otsuka Holdings Co., Ltd.'s (TSE:4578) 24% Undervaluation?

Apr 20

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Mar 15

Gelir ve Gider Dağılımı

Otsuka Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

TSE:4578 Gelir, gider ve kazançlar (JPY Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 24	2,269,564	151,575	923,851	312,313
30 Jun 24	2,179,961	126,817	888,794	309,650
31 Mar 24	2,089,741	137,563	845,547	312,223
31 Dec 23	2,018,568	121,616	807,355	307,804
30 Sep 23	1,950,959	184,702	777,521	297,102
30 Jun 23	1,871,228	166,860	757,007	292,125
31 Mar 23	1,806,034	172,194	745,187	283,851
31 Dec 22	1,737,998	133,906	724,129	275,230
30 Sep 22	1,656,978	109,845	706,655	263,543
30 Jun 22	1,593,768	103,809	678,679	254,588
31 Mar 22	1,541,795	104,036	642,606	243,043
31 Dec 21	1,498,276	125,463	622,326	232,299
30 Sep 21	1,463,284	147,019	596,462	221,303
30 Jun 21	1,446,198	152,734	579,099	210,550
31 Mar 21	1,420,055	155,109	562,954	211,122
31 Dec 20	1,422,826	148,137	562,434	216,841
30 Sep 20	1,434,441	143,398	560,802	219,909
30 Jun 20	1,420,552	146,198	558,797	224,980
31 Mar 20	1,421,844	145,709	563,043	219,069
31 Dec 19	1,396,240	127,151	557,607	215,789
30 Sep 19	1,372,665	116,333	562,504	211,273
30 Jun 19	1,344,787	86,379	567,319	220,080
31 Mar 19	1,311,287	78,918	571,343	224,569
31 Dec 18	1,291,981	82,492	564,374	216,140
30 Sep 18	1,269,004	117,106	551,893	212,434
30 Jun 18	1,262,916	133,942	544,768	190,872
31 Mar 18	1,254,410	114,206	557,945	181,513
31 Dec 17	1,239,952	112,492	558,677	175,558
30 Sep 17	1,211,772	75,029	565,791	185,597
30 Jun 17	1,196,154	88,267	557,511	177,785
31 Mar 17	1,193,159	94,933	535,629	169,451
31 Dec 16	1,195,547	92,563	535,852	168,818
30 Sep 16	1,240,874	71,521	504,554	164,309
30 Jun 16	1,294,177	61,301	532,243	177,728
31 Mar 16	1,342,728	68,735	546,741	192,335
31 Dec 15	1,445,227	84,053	597,350	201,010
31 Dec 14	1,599,424	151,237	630,029	255,907
30 Sep 14	1,541,631	163,443	602,577	246,447
30 Jun 14	1,515,577	156,499	577,133	247,685
31 Mar 14	1,452,759	150,956	542,805	249,010
31 Dec 13	1,403,125	174,046	491,656	241,922

Kaliteli Kazançlar: 4578 büyük bir tek seferlik zarar ile ¥236.9B, 30th September, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: 4578 'nin mevcut net kar marjları (6.7%) geçen yılın (9.5%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 4578 şirketinin kazancı son 5 yılda yılda 1.4% oranında arttı.

Büyüme Hızlandırma: 4578 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: 4578 geçtiğimiz yıl negatif kazanç büyümesine ( -17.9% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 38.7% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: 4578 'nin Özsermaye Getirisi ( 6.1% ) düşük olarak değerlendiriliyor.

Otsuka Holdings Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 1/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Recent updates

Earnings Miss: Otsuka Holdings Co., Ltd. Missed EPS By 10% And Analysts Are Revising Their Forecasts

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2024 Results on Feb 14, 2025

Otsuka Holdings Co., Ltd.'s (TSE:4578) Price In Tune With Earnings

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Price target increased by 7.8% to JP¥7,914

Calculating The Intrinsic Value Of Otsuka Holdings Co., Ltd. (TSE:4578)

Otsuka Holdings Co., Ltd. Just Beat EPS By 57%: Here's What Analysts Think Will Happen Next

First half dividend of JP¥60.00 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. (TSE:4578) announces an Equity Buyback for 10,000,000 shares, representing 1.84% for ¥50,000 million.

Now 21% undervalued

Otsuka Holdings Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Getting In Cheap On Otsuka Holdings Co., Ltd. (TSE:4578) Might Be Difficult

Price target increased by 9.7% to JP¥6,823

Upcoming dividend of JP¥60.00 per share

Now 22% undervalued

Otsuka Holdings Co., Ltd. Provides Earnings Guidance for the Year 2026

Now 21% undervalued

Otsuka Holdings Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Is There An Opportunity With Otsuka Holdings Co., Ltd.'s (TSE:4578) 24% Undervaluation?

Final dividend of JP¥60.00 announced

Is Otsuka Holdings (TSE:4578) A Risky Investment?

Otsuka Holdings Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Otsuka Holdings Co., Ltd. Announces Year-End Dividend for the Year Ended December 31, 2023, Payable on March 29 , 2024; Provides Second Quarter-End Dividend Guidance for the Fiscal Year 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Revises Dividend for the Full Year Ending December 31, 2023, Payable on March 29 , 2024

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ended December 31, 2023

Upcoming dividend of JP¥50.00 per share at 1.9% yield

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2023 Results on Feb 14, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Now 21% undervalued

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. to Report Q3, 2023 Results on Oct 31, 2023

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half of Fiscal Year 2023

Otsuka Pharmaceutical Co., Ltd. Announces Positive Results of Phase III Trial in Japan Showing Reduced Agitation in Patients with Alzheimer's Dia Treated with Brexpiprazole

Upcoming dividend of JP¥50.00 per share at 1.8% yield

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Jul 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

Otsuka Holdings Co., Ltd., Annual General Meeting, Mar 30, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Otsuka Holdings Co., Ltd. Provides Dividend Guidance for Fiscal Year Ending 2023

Otsuka Pharmaceutical Co., Ltd. (Otsuka) Files an Application in Japan for an Additional Indication for Rexulti

Now 23% undervalued after recent price drop

Otsuka Holdings Co., Ltd. to Report Fiscal Year 2022 Results on Feb 14, 2023

Upcoming dividend of JP¥50.00 per share

Now 21% undervalued

Otsuka Medical Devices Co., Ltd. and Recor Medical, Inc. Announce Submission of Application for Pre-Market Approval of the Paradise uRDN to the U.S. FDA

Otsuka Holdings Co., Ltd. Revises Consolidated earnings Guidance for the Fiscal Year Ending December 31, 2022

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Otsuka Holdings Co., Ltd. Revises Consolidated Earrings Guidance for the Fiscal Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

U.S. FDA Acceptance of New Drug Application for Aripiprazole 2-Month by Otsuka America Pharmaceutical, Inc

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. Revises Consolidated Earnings Guidance for the First Half Ended June 30, 2022

Price target increased to JP¥4,725

Otsuka Holdings Co., Ltd. to Report Q2, 2022 Results on Jul 29, 2022

Upcoming dividend of JP¥50.00 per share

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Otsuka Holdings Co., Ltd. Provides Consolidated Earnings Guidance for the Second Quarter of Fiscal Year Ending December 31, 2022; Provides Earnings Guidance for the Year Ending December 31, 2022

Otsuka Holdings Co., Ltd. to Report Q1, 2022 Results on May 13, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind